This Houston-based couple used their own experience of paying down consumer debt to launch a new company. Image courtesy of SpenDebt

Kiley and Ty'Lisha Summers once found themselves nearly $100,000 in debt; now, they have a goal of owning a $100 million company. The Houston-based couple used their own experience of paying down consumer debt to launch SpenDebt, a SaaS payment solution chosen for the Mastercard Start Path program.

You could say debt is ubiquitous in the United States. A 2015 report by The Pew Charitable Trusts found that 80 percent of American households have some form of debt. "As we started sharing our story, we realized that there were so many people who were just like us but didn't know what to do," explains Ty'Lisha, co-founder of SpenDebt.

SpenDebt's model relies on the simple truth: everyone spends money. The company, which is available as a phone app or web service, securely links to the user's bank account and allows you to designate a predetermined micropayment to be deducted at every transaction. The micropayments are then applied monthly to the debt of the user's choice, whether it be lofty student loans or a monthly car payment.

"God gave my husband the vision to start SpenDebt to help people help themselves," she says. Kiley even decided to share his concept Mastercard, but the idea was too early to gain anything other than the corporation's intrigue.

After two years of development and a subsequent year of beta testing, SpenDebt launched its commercialized product in 2019. The Summers applied to Mastercard Start Path, a highly competitive startup engagement program multiple times before being accepted into its 2021 cohort of six scaling startups.

"To finally get the 'yes,' it just made it full circle," says Ty'Lisha. "It's a game changer for SpenDebt."

Ty'Lisha Summers is the co-founder of SpenDebt. Photo courtesy

Fintech is a multibillion-dollar industry, and financial apps have become the darlings of venture capitalism. According to a SpenDebt release, companies that have participated in Start Path have gone on to raise more than $3 billion in post-program capital. Even while investor budgets were trimmed during the pandemic, Fintech companies garnered $44 billion in investments — a 14 percent increase since 2019, reports Finextra.

From the New Statesman to the Raconteur, media outlets and pundits have explored the saturation of the fintech sector. Ty'Lisha is confident that SpenDebt is different from its competitors.

"What's unique is that we give our customers 100 percent control on defining what that micropayment is, unlike our competition where it is strictly just round-up," she explains. The average SpenDebt user has set a $1.70 micropayment, but the co-founders have seen payments set at anything from 50 cents to $25 per transaction.

Initiatives like Bank of America's Keep the Change rounds up each transaction to the nearest dollar amount, then puts that money into a savings account for you to pay your debt off — or not. McKinsey & Company survey reports that more than 50 percent of US consumers expect to spend extra as COVID-19 restrictions relax, with higher-income millennials intending to spend the most. According to CNBC, Gen Z shoppers are also predicted to spend big on niceties like clothing and travel.

Though no app can automate personal discipline, SpenDebt can help you pay down debt and build financial literacy.

"With SpenDebt, once you tell us where you want that payment to go, that's where it's going," explains Ty'Lisha. When the micropayments are deducted from your account, SpenDebt holds onto your accrued payments and sends them monthly to the creditor of your choice. Ty'Lisha notes the service can be canceled or put on hold.

NBC News reported that 46 percent of Americans wiped out their emergency funds in 2020 as they shuffled to make ends meet. States around the country, including Texas, even enacted moratoriums on utility shut-offs in response to the pandemic. In some industries, "businesses went from collecting full payments from people to not collecting anything" or accepting partial payments, she explains.

The pandemic highlighted an opportunity for SpenDebt to partner with enterprises to offer creative solutions for payments that help customers pay off existing debt while helping businesses collect "something versus nothing."

As SpenDebt includes enterprises in its long-term growth strategy, the company founders have also pledged to work with nonprofits.

For the Summerses, SpenDebt's mission surpasses their desire to live a debt-free life. "As a part of our debt-free journey, we couldn't help but become more well-versed in finances. We were on a quest to make our money work for us versus the other way around," shares Ty'Lisha.

As Black business owners, Kiley and Ty'Lisha want to focus on building generational wealth for their family's future and help SpenDebt users do the same. "We like to say that we want all of the generational curses that may have been passed down to us to stop with us, and to start creating generational wealth for our future," she explains.

"[Debt] doesn't just address the middle class; there are so many people across the spectrum in debt," says Ty'Lisha. "A lot of times, the low-to-moderate income communities get overlooked," she continues.

SpenDebt is a preferred partner of United Way of Greater Houston and recently penned a partnership with Impact Hub Houston — an incubator with a mission to empower entrepreneurs and small businesses to take on issues like sustainability, gender equality, and economic growth.

SpenDebt hopes to capture its first enterprise customer during its six-month StartPath program and hopes to one day become a $100 billion company. "The resources, the network, the knowledge that we're getting from Mastercard and their network, the exposure that we're getting—it's going to be huge," says Ty'Lisha.

Of the many goals for SpenDebt's future, she wants the company to be "a solution for communities that may have been overlooked."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from eaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in the HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”